All lobbying filings

MEHLMAN CONSULTING, INC.

Lobbying for THE CAMPAIGN FOR SUSTAINABLE RX PRICING · A coalition of organizations working on market-based solutions to drug pricing.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $90,000.00 income · posted Jul 21, 2025

Official filing document

Bills named in this filing 14

S 229
DTC Act of 2025
HR 3789
DTC Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1302
Increasing Transparency in Generic Drug Applications Act
S 1954
Biosimilar Red Tape Elimination Act
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 1095
Stop STALLING Act
S 1097
Interagency Patent Coordination and Improvement Act of 2025
S 43
Skinny Labels, Big Savings Act
HR 3269
ETHIC Act
S 2276
ETHIC Act

Lobbying activity 3

Medicare/Medicaid

Prescription drug pricing issues. S. 229 Drug-price Transparency for Consumers (DTC) Act. H.R. 3789 - The Drug-price Transparency for Consumers (DTC) Act. H.R. 1 - One Big Beautiful Bill Act.

Pharmacy

Prescription drug pricing issues. H.R. 1843/S. 1302 - Increasing Transparency in Generic Drug Applications Act. S. 1954 - Biosimilar Red Tap Elimination Act.

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - ETHIC Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.